Documents conscious sedation with patient selection, monitoring parameters, and recovery assessment. Use when providing dental sedation, documenting sedation monitoring, or managing sedation recovery.
Documents the ASA sedation continuum for dental patients, including patient selection, pre-sedation assessment, intraoperative monitoring, drug protocols, and discharge criteria for minimal, moderate, and deep sedation.
Sedation-related adverse events are the leading cause of dental office mortality. Between 2000 and 2020, over 100 documented deaths in US dental offices were attributable to sedation complications — most involving airway compromise in inadequately monitored patients. The ASA sedation continuum means that every patient receiving sedation can unpredictably progress to a deeper level, and the provider must be trained and equipped to rescue from one level deeper than intended.
State dental boards regulate sedation permits with specific staffing, equipment, training, and documentation requirements that vary by sedation level. This skill structures the entire sedation workflow from patient selection through discharge, ensuring compliance with ADA Guidelines for the Use of Sedation and General Anesthesia by Dentists (2016, revised) and state-specific regulations.
| Level | Responsiveness | Airway | Spontaneous Ventilation | Cardiovascular | ADA Permit Level |
|---|---|---|---|---|---|
| Minimal sedation (anxiolysis) | Normal response to verbal stimulation | Unaffected | Unaffected | Unaffected | May not require separate permit (state-dependent) |
| Moderate sedation | Purposeful response to verbal or light tactile stimulation | No intervention required | Adequate | Usually maintained | Moderate sedation permit required |
| Deep sedation | Purposeful response only to repeated or painful stimulation | Intervention may be required | May be inadequate | Usually maintained | Deep sedation/GA permit required |
| General anesthesia | Unarousable even with painful stimulus | Intervention often required | Frequently inadequate | May be impaired | GA permit required; anesthesiologist or CRNA in most states |
| Assessment | Technique | Risk Indicator |
|---|---|---|
| Mallampati classification | Patient seated, mouth open, tongue protruded without phonation | Class III–IV: increased difficult airway risk |
| Thyromental distance | Mentum to thyroid notch | < 6 cm: potential difficult intubation |
| Mouth opening | Interincisal distance | < 3 cm: limited airway access |
| Neck mobility | Extension range | Limited extension: may complicate airway management |
| BMI | Weight/height² | > 35: increased desaturation risk, difficult mask ventilation |
| Neck circumference | Circumference at thyroid cartilage | > 17 inches (male) / > 16 inches (female): OSA risk factor |
| Parameter | Device | Recording Frequency | Action Threshold |
|---|---|---|---|
| Pulse oximetry (SpO₂) | Continuous pulse oximeter | Continuous; record q5 min | SpO₂ < 95%: stimulate, reposition airway; < 90%: supplemental O₂, assist ventilation |
| Heart rate | Pulse oximeter or ECG | Continuous; record q5 min | < 50 or > 120: assess and intervene |
| Blood pressure | Automated NIBP cuff | q5 min during sedation | SBP < 90 or > 180: assess and intervene |
| Respiratory rate | Visual observation or capnography | Continuous observation; record q5 min | < 8: stimulate, consider reversal; apnea > 15 sec: assist ventilation |
| End-tidal CO₂ (ETCO₂) | Capnography (nasal cannula with CO₂ sampling) | Continuous (required for moderate+ in many states) | > 50 mmHg or absent waveform: assess ventilation |
| Level of consciousness | Verbal/tactile stimulation | q5 min during sedation | Failure to respond purposefully to verbal: sedation has deepened beyond moderate |
| Temperature | Thermometer (if GA or prolonged sedation) | Pre and post procedure | > 38.5°C unexplained: consider MH in susceptible patients |
| Route | Drugs | Typical Adult Dose | Onset | Notes |
|---|---|---|---|---|
| Oral (minimal) | Triazolam | 0.25–0.5 mg SL | 15–30 min | Titrate; elderly start at 0.125 mg |
| Oral (minimal) | Diazepam | 5–10 mg PO | 30–60 min | Long half-life; delayed recovery |
| Inhalation (minimal) | Nitrous oxide/oxygen | 30–50% N₂O titrated | 3–5 min | Self-limiting; rapid recovery |
| IV (moderate) | Midazolam | 1–2 mg initial, titrate 0.5 mg q2 min | 1–3 min | Max ~5 mg in healthy adult; reduce in elderly |
| IV (moderate) | Fentanyl | 25–50 mcg initial, titrate 25 mcg q5 min | 2–3 min | Respiratory depression risk; have naloxone ready |
| IV (deep/GA) | Propofol | Induction 1–2 mg/kg; infusion 25–75 mcg/kg/min | 30–60 sec | Requires deep sedation or GA permit; dedicated anesthesia provider |
| Agent | Reverses | Dose | Route | Onset | Duration |
|---|---|---|---|---|---|
| Flumazenil | Benzodiazepines | 0.2 mg initial, repeat 0.2 mg q1 min (max 1 mg) | IV | 1–2 min | 45–90 min (re-sedation possible) |
| Naloxone | Opioids | 0.4 mg initial, repeat q2–3 min | IV/IM | 1–2 min IV, 5 min IM | 30–90 min (re-sedation possible; patient must be monitored) |
| Criterion | Score 2 | Score 1 | Score 0 |
|---|---|---|---|
| Activity | Moves all extremities voluntarily | Moves 2 extremities | Unable to move |
| Respiration | Deep breath, coughs freely | Dyspnea or limited breathing | Apneic |
| Circulation | BP ± 20% of pre-sedation | BP ± 20–49% of pre-sedation | BP ± 50% of pre-sedation |
| Consciousness | Fully awake | Arousable on calling | Not responding |
| Oxygen saturation | SpO₂ > 95% on room air | Needs supplemental O₂ for SpO₂ > 90% | SpO₂ < 90% with supplemental O₂ |
Minimum discharge score: 9 out of 10 (no zeros in any category).
| Requirement | Specification |
|---|---|
| Pre-sedation assessment | Age-appropriate airway evaluation; weight-based drug dose calculation documented |
| NPO requirements | Same as adult ASA guidelines; verify with caregiver |
| Monitoring personnel | Dedicated observer in addition to operator for moderate sedation |
| Weight-based dosing | All drugs calculated by mg/kg; maximum dose documented BEFORE administration |
| Discharge criteria | Age-appropriate responsiveness; return to pre-sedation level of consciousness; adequate hydration |
| Documentation | Include weight, calculated dose, administered dose, monitoring parameters, Aldrete or equivalent score |
| Drug | Pediatric Dose | Maximum | Risk |
|---|---|---|---|
| Oral midazolam | 0.5 mg/kg (max 20 mg) | 20 mg | Paradoxical reaction (agitation instead of sedation) in ~2% of children |
| Oral hydroxyzine | 2 mg/kg | 50 mg for < 6 years; 100 mg for ≥ 6 years | Excessive sedation when combined with other agents |
| Intranasal midazolam | 0.2–0.3 mg/kg | 10 mg | Burning sensation on administration |
| Nitrous oxide | 30–50% titrated | 50% N₂O | Nausea risk increases above 50% |
| Oral chloral hydrate | 50–75 mg/kg | 1 gram for infants; 2 grams for children | Narrow therapeutic window; respiratory depression; prolonged recovery — increasingly avoided |
| # | Criterion | Pass / Fail |
|---|---|---|
| 1 | State sedation permit current and displayed | |
| 2 | Pre-sedation medical evaluation documented within 30 days | |
| 3 | ASA classification and Mallampati score recorded | |
| 4 | NPO status confirmed and documented before sedation | |
| 5 | Informed consent for sedation obtained separately from procedure consent | |
| 6 | Monitoring devices calibrated and functioning before start | |
| 7 | Vital signs recorded at minimum q5 min intervals | |
| 8 | Capnography used for moderate sedation and above (per state requirement) | |
| 9 | Emergency equipment and reversal agents immediately available | |
| 10 | Dedicated monitor present for moderate sedation; dedicated anesthesia provider for deep/GA | |
| 11 | Drug doses, routes, and times documented in sedation record | |
| 12 | Modified Aldrete score ≥ 9 documented at discharge | |
| 13 | Responsible escort confirmed before patient release | |
| 14 | Post-sedation instructions provided in writing | |
| 15 | Staff ACLS/PALS certifications current per state requirement |